gold ticket drug immun checkpoint
initi outperform
checkpoint modul cpm act immun system rather
underli diseas revolution treatment certain cancer
autoimmun disord alpin immun develop differenti platform
technolog believ could significantli improv perform cpm
benefit patient two lead product base
natur checkpoint bind partner engin new fit-
for-purpos function found mitch gold earli champion immuno-
oncolog believ alpin deserv spot investor radar despit
preclin stage compani initi coverag outperform price
convent cpm monoclon antibodi contrast alpin product
new class cpm base variant immunoglobulin domain vigd
engin scaffold natur checkpoint ligand alpin use
iter process direct evolut impart vigd bind properti
best suit given applic vigd simultan
believ alpin multifunct vigd possess sever advantag
convent cpm includ bispecif antibodi provid
physiolog nativ approach agon antagon checkpoint
manufactur effici monoclon antibodi
alpin lead therapeut candid autoimmun diseas slate
enter clinic earli drug simultan block ico
two import checkpoint control activ durat immun
respons preclin model dual blockad target
block approv product orencia proven
success therapeut strategi inflammatori autoimmun diseas
gvhd rheumatoid arthriti preclin model gvhd arthriti
demonstr superior abil quench inflamm rel
orencia
alpin lead immuno-oncolog product slate enter
clinic drug strike chord checkpoint agon
simultan block believ could
blockbust potenti improv perform approv cpm
combin therapi opdivo yervoy advanc melanoma
alpin immun scienc emerg
biotechnolog compani focus
develop novel immunotherapi
cancer autoimmun disord
analyst certif import disclosur see disclosur
success clinic develop
us eu commerci use
us eu commerci use
combin sale
approv success commerci
autoimmun disord rheumatoid arthriti lupu
approv success commerci
solid tumor indic
earlier anticip regulatori commerci approv
collabor partnership substanti mileston payment
exist collabor gilead
new
believ alpin immun scienc proprietari
vigd-bas immunotherapi uniquely-posit develop
new class checkpoint modul improv
avail therapi autoimmun diseas cancer
valuat center commerci potenti
graft-vs-host diseas advanc melanoma
potenti present updat preclin data
potenti present updat preclin data
potenti file ind
potenti initi first-in-human studi healthi
potenti file ind solid tumor
potenti initi phase studi acut gvhd
potenti initi studi monotherapi variou
failur and/or advanc clinic
product delay reduc commerci potenti
month price target base risk-adjust sum-of-th part npv contribut
includ alpin project cash per share arriv price target
risk includ price clinic regulatori financ market competit
alpin immun scienc seattl wa-bas biotechnolog compani
focus develop immunotherapi treatment
autoimmun disord cancer alpin technolog platform base
engin variant immunoglobin superfamili igsf protein call vigd
potent new class checkpoint modul alpin vigd
gener iter process mutagenesi vitro select alter
natur bind properti checkpoint ligand like bispecif antibodi vigd
assembl multival fit-for-purpos construct vigd platform
highli modular use gener stand-alone product integr
cancer cell therapi compani enter research
collabor kite pharma gilead grant kite access two novel
vigd construct use next-gener car-t product collabor
remain activ follow kite acquisit includ up-front
development clinic regulatori mileston payment
addit royalti success commerci product base
vigd alpin two lead product
develop use autoimmun disord immuno-oncolog respect
compani incorpor went public juli
revers merger former
initi coverag alpin immun scienc outperform rate
price target next month believ compani novel
vigd-bas therapi potenti improv safeti efficaci
convent checkpoint modul expand reach benefit
patient although alpin deploy vigd-bas therapeut varieti
role current ascrib valu compani two lead product
current slate enter clinic
alpin advanc program dual inhibitor two immun
checkpoint ico develop acut chronic
inflammatori disord graft-versus-host diseas gvhd serv
proof-of-concept indic preclin evid suggest
potent immunosuppress activ rel relat product orencia
alpin expect file ind end year
see alpin vigd platform especi well-suit agon
activ immun checkpoint view vigd-bas agonist could provid
eleg solut drug certain pathway especi case
agon antibodi difficult gener second product
packag uniqu combin inhibitori agonist domain singl
construct dualli inhibit like bavencio imfinzi ctla-
like yervoy simultan activ note combin
therapi dualli block pathway
therapeut proven approach melanoma alpin gener
preclin evid suggest may improv safeti
efficaci combin discuss report believ co-stimul
may bring best qualiti inhibit
repres sophist three-prong approach checkpoint modul
packag singl drug
concurr initi alpin also initi coverag
synthet biotic pioneer synlog inc outperform rate
methodolog summar exhibit model includ contribut
two differ program treatment steroid-refractori acut
gvhd probabl success regulatori approv commerci
launch treatment advanc metastat
melanoma po regulatori approv commerci launch
believ risk adjust larg line histor data
success rate drug base current stage develop natur
review drug discoveri elect use slightli higher
po rel therapeut develop
autoimmun disord histor success oncolog
biostatist doi elect use discount
rate given inher riski drug develop
sum-of-part valuat two program summar
includ project cash posit per share total npv
sum
exhibit part valuat mari
invest thesi depend alpin abil success develop
manufactur commerci therapi date alpin
demonstr clinic proof-of-concept product run
clinic trial manufactur clinical-grad therapi assess
potenti base preclin studi
compani may experi delay complet clinic trial result
earli trial may predict result registr clinic trial
alpin abl success develop commerci
may face price pressur payer alpin may also face ip
relat risk novel therapi deem infring issu patent
competit product due earli develop stage
compani may choos priorit develop either drug
indic gvhd melanoma
major development-stag biotechnolog compani abil
maintain suffici fund critic develop progress pipelin
candid current alpin cash flow neg model
multipl dilut rais may necessari sustain oper
compani potenti achiev sustain profit addit
stock somewhat limit float possibl addit suppli lock-up
pipelin clinic program
potenti present updat preclin data
potenti file ind
potenti initi first-in-human studi healthi volunt
potenti initi phase studi acut gvhd
potenti present updat preclin data
potenti file ind
potenti initi studi monotherapi variou tumor type
compani present oppenheim co estim
platform technolog aim
hit right checkpoint button
immun checkpoint modul cpm class drug
revolution treatment cancer autoimmun diseas cpm dial
dial immun system act molecular check balanc
keep immun respons tightli regul exampl cpm act
pathway block inhibitori signal instruct t-cell stand
block signal drug like keytruda opdivo bavencio
tecentriq imfinzi releas brake t-cell mediat anti-tumor activ
past five year inhibitor experienc widespread
uptak oncolog increasingli util front-lin therapi
rel larg indic lung cancer melanoma cpm
orencia nulojix act suppress immun system strategi
demonstr clinic success variou autoimmun diseas
rheumatoid arthriti psoriat arthriti solid organ transplant
class cpm act immun system rather underli
diseas elicit highli durabl multi-year respons unfortun cpm
still far univers solut work patient
alpin develop next-gener class cpm base vigd platform
illustr exhibit vigd immunoglobulin superfamili igsf domain
engin interact variou immun checkpoint
combin vigd specif one target differ
vigd assembl multival combin depend desir
target pharmacokinet exampl vigd express fusion
therapeut monoclon antibodi mab antibodi fragment
fc domain principl fuse vigd therapeut mab herceptin
could facilit local immun stimul site tumor drug base
vigd manufactur similar process convent mab
alpin platform consider versatil
rel simpl construct contain singl multispecif vigd
coupl antibodi fc domain
exhibit vigd assembl multipl construct
addit fc mab fusion alpin vigd also deploy
membrane-anchor co-stimulatori receptor convers decoy receptor
improv activ engin t-cell therapi chimer antigen
receptor -t cell product kite pharma gilead forg collabor
around two alpin transmembran immunomodulatori protein tip
use cell therapi addit fulli secret immunomodulatori protein
sip essenti nake vigd could directli engin
cancer cell therapi improv safeti efficaci
sculpt natur checkpoint ligand
immun system rheostat includ dozen checkpoint signal
pathway tightli regul activ inhibitori signal immun cell
receiv variou tissu bodi checkpoint activ repress
cell innat adapt arm immun system complex
checkpoint/ligand interplay exist tumor effector t-cell helper t-cell
regulatori t-cell nk cell myeloid cell see exhibit
checkpoint effect drug mab case natur
checkpoint ligand har potent cpm vigd
deriv endogen checkpoint ligand believ capac
either activ inhibit immun respons physiolog natur
way rel antibodi
exhibit select checkpoint-ligand interact immun synaps
checkpoint ligand gener belong ig superfamili mani capabl
bind one partner exampl ligand also known
interact inhibitori checkpoint stimulatori
checkpoint t-cell hit could lead
robust activ t-cell could achiev specif mab
yervoy
alpin lead vigd-bas therapeut base ico ligand
icosl igsf protein hand base
product engin vigd fuse fc
domain impart mab-lik pharmacokinet profil product
structur reminisc mab illustr exhibit variabl region
usual present mab replac vigd
exhibit vigd-bas therapeut distinct convent mab
adapt alpin immun scienc corpor present may opco research
build new function igsf domain
use igsf domain cpm entir new concept orencia
relat product nulojix fusion protein consist extracellular igsf
domain fuse antibodi fc domain
immunosuppress drug gener combin sale unfortun
mani igsf domain possess less-than-id bind properti
unwant bind promiscu and/or low bind affin would make
poor candid drug fortun igsf protein toler wide varieti
perturb surfac amino acid without perturb core
architectur alpin core ip built around principl igsf domain
engin mutat specif amino acid nativ igsf scaffold
enhanc restrict interact bind partner wide rang
checkpoint-ligand interact character atom level
academ commun specif bind site alter introduc
ration semi-r fashion word interact two
bind partner poison strengthen though iter process
mutat select novel checkpoint bind site even
introduc onto igsf domain without compromis nativ bind site
exampl igsf use nativ capac
bind alpin engin vigd increas
affin addit novel bind site
similarli vigd featur increas bind affin ico
novel bind site exampl engin igsf
emerg alpin platform summar exhibit arrow
indic enhanc bind affin wherea arrow indic reduc bind
exhibit direct evolut platform modul vigd bind properti
manufactur breez rel bispecif
although bispecif antibodi bsab also use simultan target
multipl checkpoint pathway believ alpin approach inher
manufactur effici asymmetr bsab consist two variabl
fragment pair correctli full function lead low-effici
manufactur contrast alpin vigd approach least
entir sidestep issu util symmetr design
multi-target bind engin directli vigd
take aim
alpin lead clinic candid slate ind file late
illustr exhibit contain icosl vigd
engin simultan bind addit natur bind partner
ico ico import checkpoint involv activ
immun cell believ dual blockad target achiev
profound immunosuppress inhibit either target alon notabl
target alon orencia and/or nulojix alreadi proven
success therapeut strategi inflammatori autoimmun diseas
especi rheumatoid arthriti sever preclin model
demonstr superior abil quench inflamm
exhibit dual antagonist inflammatory/autoimmun
alpin plan investig sever autoimmun disord
begin steroid refractori acut graft-versus-host diseas agvhd
see agvhd ideal prove ground diseas devast
complic allogen stem cell transplant patient fail front-lin
steroid current consensu second line therapi
prove effect safe clinic believ drug could benefit
expedit pathway market howev also believ could
use treat varieti inflammatori autoimmun diseas
rheumatoid arthriti lupu repres much larger market
re-engin icosl antagon ico
engin version icosl lie heart icosl
normal express antigen present cell apc bind
stimulatori ico checkpoint t-cell direct evolut alpin
develop icosl-bas vigd improv affin ico ad
new bind site compet ico shown exhibit
nativ icosl normal affin engin vigd bind
target
exhibit capabl dual bind new
preclin demonstr profound anti-inflammatori activ
sever model autoimmun diseas includ gvhd rheumatoid
arthriti acut gvhd consequ allogen stem cell transplant
aris donor t-cell attempt mount respons healthi tissu
recipi name impli acut gvhd sudden onset within day
mix lymphocyt reaction common vitro assay use assess
alloreact donor t-cell host tissu alpin perform seri
mlr sever differ icosl-bas vigd differ affin
ico shown exhibit vigd demonstr affinity-
depend reduct t-cell activ includ t-cell
measur cell prolifer cytokin ifn tnf releas
word vigd tightest bind ico potent
immunosuppress effect rel belatacept nulojix sever alpin
exhibit icosl vigd-fc protein suppress t-cell respons vitro
american societi hematolog annual meet abstract
result recapitul mous model gvhd
perform inject human peripher blood cell mice shown
mice treat higher affin vigd especi variant
demonstr improv overal surviv lower diseas activ index score
rel belatacept consist reduc autoimmun mice treat
exhibit icosl-bas vigd protect mice gvhd
american societi hematolog annual meet abstract
icosl-bas vigd also evalu wide use collagen-induc
rodent model rheumatoid arthriti ra shown exhibit first-gener
icosl vigd-fc construct control inflamm measur mean sum paw
score better abatacept antibodi inflammatori collagen agent
reduc icosl vigd-fc abatacept-tr mice rel placebo
exhibit icosl vigd outperform abatacept mous model ra
american colleg rheumatolog annual meet abstract
mechan action
ico co-stimulatori checkpoint express effector t-
cell play uniqu role t-cell activ regard
central gatekeep t-cell respons requir prime nave t-
cell initi new respons propag on-going t-cell respons
contrast induc co-stimul ico checkpoint constitut
express rest t-cell rapidli induc prime ico
play role initi new respons may essenti
maintain momentum front immunol aug
prevent bind ico natur partnersbut
keep base natur ligand ico
activ target possibl answer disrupt
recruit ico checkpoint locat need act
exampl natur ligand recruit close proxim
t-cell receptor tcr interact tcr site requir
stimul t-cell growth prolifer contrast like prevent
recruit tcr site
similar principl may appli ico co-stimul ico biolog
yet fulli elucid icosl like activ ico signal receptor
dimer could block icoss abil dimer howev
note ico express upregul helper t-cell
regulatori t-cell treg immunosuppress activ could
partial attribut stimul icos-express treg front immunol
aug regardless perform rel abatacept
orencia balatacept nulojix preclin model lead us believ
ico play import role co-stimulatori checkpoint
valid target gvhd
due central role t-cell activ must care regul
prevent runaway immun respons regul well-character
checkpoint upregul follow t-cell prime effect
outcompet bind shut co-stimulatori
pathway safeti mechan fail patient develop sever
autoimmun diseas previous mention orencia fc fusion
protein current evalu investigator-sponsor studi
gvhd view trial yield impress result
could read-through
studi investig administ four dose orencia day
patient undergo allogen transplant mismatch
unrel donor notabl mismatch unrel donor transplant rare
due high risk uncontrol gvhd orencia ad standard
prophylact includ steroid calcineurin inhibitor methotrex
cohort patient prophylact use orencia associ mark
reduct cumul incid acut gvhd rel histor
control arm mismatch patient exhibit caution use
histor compar arm transplant trial believ outcom
line outcom associ safer graft choic match
exhibit blockad orencia show impress gvhd control
american societi hematolog annual meet abstract
target ico may assist blockad
come cpm believ insight gain oncolog inform drug
develop autoimmune/inflammatori disord cancer immun
system hamstrung insuffici co-stimul target
checkpoint ipilimumab yervoy mab proven
effect therapeut strategi note ipilimumab activ distinct
subset t-cell character express ico demonstr
recent publish studi use biopsi cpm-treat melanoma
patient cell sep specif studi
compar tumor-infiltr t-cell cpm-treat melanoma patient t-
cell peripher blood collect healthi donor patient
previous receiv yervoy expans icos-posit effector t-cell
popul observ view observ tie togeth import
physiolog link ico offer rational dualli
target ico checkpoint
steroid refractori gvhd indic high unmet
acut gvhd fatal approxim transplant patient
higher risk mismatch donor/recipi bone marrow tran
treatment current avail gvhd lead seriou downstream
consequ front-lin system steroid effect patient
blood use steroid immunosuppress
reflex increas incid sever infect risk leukemia
relaps opinion urgent need drug specif
target inflam tissu without systemat disabl entir immun
front line therapi agvhd typic consist methylprednisolon mg/kg
per day seven day monitor respons three day skin
and/or four day organ involv patient condit worsen
addit therapi top steroid advoc
get agvhd control quickli ideal within first day critic
patient outcom prospect studi demonstr outcom gvhd
treatment correl treatment-rel mortal two year post-
transplant half patient uncontrol gvhd day
respons treatment dead two year see exhibit
reason fda current accept day respons rate surrog endpoint
clinic studi steroid-refractori agvhd
univers grade scale agvhd exist clinician use either
ibmtr scale brit haematol glucksberg scale
transplant system group gvhd sever four
categori basi gvhd involv three organ skin liver
gut ibmtr scale exhibit classifi overal sever base worst
organ score measur respons rate complet respons cr therapi
defin complet remiss diseas involv organ partial
respons pr often defin improv least one grade
organ without concomit progress anoth organ
exhibit ibmtr grade classif agvhd
martin et al cibmtr symposium acut gvhd grade endpoint
although mani drug activ investig steroid-refractori gvhd
demonstr compel activ clinic incyt
ruxolitinib grant breakthrough therapi design agvhd fda
heel impress result sever investig sponsor studi
studi treat patient grade four-steroid-refractori gvhd
orr includ leukemia
recent announc top-lin data phase
trial investig ruxolitinib adult steroid-refractori gvhd
patient day orr prompt compani announc plan
file supplement nda base result view reach-
could set bar meet beat approv adult patient
pediatr patient therapeut modal mesenchym lineag
stem cell shown promis clinic exampl mesoblast msc-
achiev respons rate steroid-refractori patient
market opportun
current ascrib valu acut steroid-refractori
gvhd indic believ offer rel low bar approv
could benefit expedit pathway market
success quench acut gvhd could see therapi move
front-lin set futur
approxim allogen stem cell transplant conduct us
eu yearli cibmtr estim bone marrow transplant jun
estim approxim patient
experi sever grade ii-iv acut gvhd approxim sever
gvhd patient becom refractori front-lin steroid use price estim
us eu line price
checkpoint modul estim market size approxim
territori combin sale project heavili risk-
adjust assum po given early-stag develop
assum approv commerci
us eu estim could gener peak non-risk-
adjust sale combin market
exhibit market model steroid refractori acut gvhd
cancer
alpin lead immuno-oncolog i/o product design
encourag anti-tumor immun act three checkpoint simultan
base igsf scaffold natur affin
checkpoint vigd use
engin novel bind site recal axi
commonli exploit cancer shut t-cell respons unlik alpn-
agonist stimul t-cell activ
block signal agon
effect releas brake step ga t-cell respons
importantli i/o combin target checkpoint
shown synergist activ melanoma patient demonstr
safer effect altern
hit checkpoint chord
thu block two import checkpoint
exploit tumor dampen anti-tumor immun illustr
exhibit bind properti allow tether express
t-cell express cancer cell proxim tcr
permit activ bridg rather individu
target checkpoint separ mab believ could
favor therapeut index rel yervoy opdivo combin
repurpos activ believ alpin develop
particularli eleg approach ensur adequ co-stimul
potenti improv efficaci current checkpoint inhibitor combin
hsct performed/year acut grade ii-iv gvhd/year front-lin system therapi cost market size sale penetr treat hsct performed/year acut grade ii-iv gvhd/year front-lin system therapi cost market size sale penetr treat profit oper expens tax probabl discount gvhd revenu gvhd us eu alpin immun scienc inc
exhibit provid dual antagon co-stimul
adapt alpin immun scienc corpor present may
recal natur affin alpin introduc
bind site vigd preserv bind affin
shown alpin gener panel vigd
fc fusion bind higher affin wild-
exhibit engin vigd bind
american associ cancer research annual meet abstract
point two recent high-profil public underscor requir
adequ co-stimul optim respons inhibitor
one studi inhibit antibodi abrog abil
block antibodi rescu exhaust t-cell scienc
second report author ira mellman
colleagu show inactiv signal suggest co-
stimulatori pathway play key role regul effector t-cell function
respons blockad scienc
intriguingli studi independ suggest product
signal may requir respons current avail checkpoint
alpin interrog abil variou vigd-fc fusion block
interact vitro present bodi
preclin data meet graph exhibit compar
bind function inhibit target versu monoclon antibodi
alpin show vigd-fc fusion elicit
robust express cytokin directli induc activ
exhibit block bind vigd
american associ cancer research annual meet abstract
exhibit express induc t-cell co-cultur
american associ cancer research annual meet abstract
importantli xenograft model refractori inhibitor
demonstr robust activ shown exhibit alpin vigd-fc
elicit superior anti-tumor activ compar approv inhibitor
durvalumab acknowledg preclin model alway hold
clinic especi i/o drug develop believ
deserv phase evalu base preclin profil
exhibit activ mous xenograft model
american associ cancer research annual meet abstract
market opportun
believ potenti use wide rang cancer
includ shown disappoint activ convent
checkpoint inhibitor alpin yet disclos target indic
believ advanc metastat melanoma could prove
ground drug like mani investig i/o agent
despit crowd competit landscap believ could gain
foothold second-lin therapi patient advanc melanoma
fail treatment frontlin antibodi despit approv
combin ipilimumab nivolumab second-lin set uptak
limit concern toxic toler
market model shown exhibit given
current develop stage anticip us eu commerci launch
us incid stage iiic-iv metastat melanoma
popul checkpoint modul antibodi
effect approxim patient front-lin option cancer
jun assum treatment price estim
us market size advanc melanoma approxim
assum modest penetr second-lin set estim
peak non-risk adjust sale us assum po base
earli stage develop
eu incid stage iiic-iv metastat melanoma
patient per year assum approxim respond front line
therapi assum averag treatment price eu
estim european market size approxim model
launch europ peak non-risk adjust sale
exhibit market model advanc melanoma
alpin activ seek protect therapeut candid composit
matter patent cover intend target method use patent
cover potenti therapeut indic decemb compani
pend patent applic issu would cover vigd-bas
therapeut includ use target evolut bestow novel bind
capabl therapeut alpin patent applic also relat use
vigd tip sip function
case primari melanoma stage iii-iv melanoma cost market size sale penetr treat case primari melanoma stage iii-iv melanoma cost market size sale penetr treat profit oper expens tax probabl discount melanoma revenu melanoma us eu pt unrespons checkpoint antibodi us pt unrespons checkpoint antibodi eu alpin immun scienc inc
alpin approxim million cash cash equival
market secur end believ compani suffici
resourc fund oper ad multipl dilut
rais model total could sustain compani
project loss
per share respect expect see increas cash burn
associ increas sg reflect compani plan ind
file
believ could approv commerci us eu
gener peak non-risk adjust sale believ
could approv commerci us eu
gener peak non-risk adjust sale
introduc estim increas
introduc estim increas
assum cog alpin therapi believ in-
line convent biolog drug mab
execut chairman chief execut offic
evp chief medic offic
execut chairman ceo
dr gold formerli serv ceo dendreon corpor team
oversaw develop success commerci first approv
dendrit cell vaccin use cancer dr gold also serv chairman
founder alpin bioscienc privat held biotech compani focus
develop novel therapi potenti best-in-class nanoparticl
execut vice presid chief medic offic
dr peng serv dual role head chief medic offic alpin
prior alpin dr peng chief medic offic stemcentrx
acquir execut director head
inflamm translat medicin prior join
industri dr peng serv member physician virginia mason medic
center assist professor divis rheumatolog
washington univers school medicin
prior join alpin paul serv cfo
serv vice-president financ immun design paul
oversaw serv corpor control northstar neurosci paul start
financ career ernst young llp certifi public account
sec file oppenheim co research
figur thousand except per share expens good sold research develop gener administr oper loss purchas loss incom incom tax benefit incom tax ratenet incom loss unreal loss incom per share share outstand comark breidenbach alpn outperform
sec file oppenheim co research
figur thousand except per share asset cash market tax expens current current market equip asset cash stockhold equitycurr liabil account clinic trial manufactur expens current tax long term equiti common paid-in comprehens incom stockhold liabil stockhold comark breidenbach alpin immun scienc inc
